VALBIOTIS
INVESTORS PRESENTATION
July 2020
01.
02.
03.
04.
05.
06.
2
VALBIOTIS / Corporate
TOTUM-63, to reduce the risk of type 2 diabetes
TOTUM-070, to reduce hypercholesterolemia
TOTUM-854, to reduce blood pressure
TOTUM-448, to reduce non-alcoholic hepatic steatosis (NAFL)
FINANCIAL INFORMATION
© NON CONFIDENTIAL
A R&D company, committed | 3 |
to scientific innovation, | |
for preventing and combating | |
metabolic diseases |
Active substances from plants and based on science, to address unmet medical needs
-
An innovative approach,
enabled by a specific expertise of plants - A high level of evidence, with clinical studies and health claims
- A pipeline of innovative active substances in Nutrition Healthcare, engineered in our R&D centers
- 4 patent families registered on 5 continents
© NON CONFIDENTIAL
4
Nutrition Healthcare:
a portfolio of active substances, in clinical stages
Phase II | Phase II/III | Study launch | Results | |
TOTUM-63 / Prediabetes | ||||
Mid-2020 | S1 2022 |
TOTUM-070 / Hypercholesterolemia | |||
Q3 2020 | Q4 2021 |
TOTUM-854 / Arterial hypertension | |||
Q4 2020 | Q1 2022 |
TOTUM-448 / Fatty Liver | |||
S2 2021 | - |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Valbiotis SA published this content on 21 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2020 05:49:06 UTC